Aytu Biopharma Inc (AYTU)

Jan 18, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St

Jan 18, 2025

Jan 06, 2025

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - AccessWire

Jan 06, 2025

Jan 06, 2025

Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan

Jan 06, 2025

Jan 02, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World

Jan 02, 2025

Dec 27, 2024

An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com

Dec 27, 2024

Dec 27, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St

Dec 27, 2024

Dec 14, 2024

Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia

Dec 14, 2024

Dec 14, 2024

Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa

Dec 14, 2024

Dec 06, 2024

Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World

Dec 06, 2024

Dec 05, 2024

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Dec 05, 2024

Dec 03, 2024

Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan

Dec 03, 2024

Dec 03, 2024

Aytu BioPharma Disclosure Notification - AccessWire

Dec 03, 2024

Dec 03, 2024

Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance

Dec 03, 2024

Nov 22, 2024

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - AccessWire

Nov 22, 2024

Nov 22, 2024

Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan

Nov 22, 2024

Nov 18, 2024

Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com

Nov 18, 2024

Nov 18, 2024

Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St

Nov 18, 2024

Nov 16, 2024

Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World

Nov 16, 2024

Nov 15, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks

Nov 13, 2024

Nov 13, 2024

Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch

Nov 13, 2024

Nov 13, 2024

Aytu BioPharma Achieves First-Ever Quarterly Profit of $1.5M, Reports 72% Margins | AYTU Stock News - StockTitan

Nov 13, 2024

Nov 13, 2024

Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500

Nov 13, 2024

Nov 08, 2024

Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia

Nov 08, 2024

Nov 05, 2024

Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail

Nov 05, 2024

Nov 05, 2024

Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR

Nov 05, 2024

Nov 01, 2024

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St

Nov 01, 2024

Nov 01, 2024

AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia

Nov 01, 2024

Oct 29, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Oct 29, 2024

Oct 23, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Oct 23, 2024

Oct 22, 2024

AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com

Oct 22, 2024

Oct 14, 2024

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire

Oct 14, 2024

Oct 11, 2024

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia

Oct 11, 2024

Oct 09, 2024

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa

Oct 09, 2024

Oct 06, 2024

Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle

Oct 06, 2024

Oct 03, 2024

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Oct 03, 2024

Oct 01, 2024

Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada

Oct 01, 2024

Oct 01, 2024

Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa

Oct 01, 2024

Oct 01, 2024

AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan

Oct 01, 2024

Oct 01, 2024

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan

Oct 01, 2024